We reported that pemafibrate significantly reduced the serum levels of AST, ALT and GGT and significantly increased serum albumin levels at 3, 6 and 12 months after the start of pemafibrate treatment in patients with hypertriglyceridemia (n = 246), with an improvement in atherogenic dyslipidemia [82]. The gene discussed is ALB; the disease is hypertriglyceridemia.